Barclays analyst Carter Gould maintained a Buy rating on Eli Lilly & Co (LLY – Research Report) today and set a price target of $975.00.

State Medicaid programs for low-income families are the single biggest source of coverage, giving 31.6 million people access ...

Tirzepatide by Eli Lilly reduces heart failure risk in adults with HFpEF and obesity, showing promising results for both ...

U.S. government health plans account for the lion's share of coverage for popular new weight-loss drugs, far beyond the ...

The United States Federal Trade Commission (FTC) filed an administrative complaint against the nation’s three largest ...

The makers of Ozempic and Zepbound are fighting to stop compounded copies of their drugs. But it’s unclear whether they can ...

The trial met both primary endpoints, with tirzepatide showing a 38% decrease in heart failure outcomes compared to placebo.

Doctors say they have not seen anything like this since the emergence of statins to lower cholesterol. But do we know enough ...

Novo Nordisk and Eli Lilly are facing scores of personal injury claims for allegedly failing to warn patients about side ...

From a travel agency battling COVID blues and an investment firm licking its wounds, to a Spanish company with a network ...

Novo Nordisk has long supplied human insulin pens to the national health department. But last year it decided not to bid for ...

Ozempic, Wegovy and other GLP-1 drugs have been shown to curb alcoholism, a new study suggests. Researchers explain why ...